CancerNCT07776587
Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients
A study testing Yoga Therapy (YT) in people with Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Yoga Therapy (YT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2027to 13 Apr 2032
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female cancer patients
- Age 18 or older
- Understand and read English
- Scheduled to undergo their first autologous or allogeneic HSCT (even number of each) at MDA with a minimum of 2-week inpatient hospital stay
- Be willing to follow protocol requirements
- Sign a written informed consent
Who cannot join
- Have extreme mobility issues that preclude participating in the Yoga program
- Have major thought disorders such as schizophrenia or uncontrolled bipolar disorder
- Have hematopoietic cell transplantation HCT comorbidity score of 3 or higher (excluding cancer)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson Cancer Center
Houston, Texas, 77030
Lorenzo Cohen, PHD, 713-745-4260, lcohen@mdanderson.org
Lorenzo Cohen, PHD
About this study
Official title: Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program.
Read the detailed description
Primary Objective:
- Examine the efficacy of YT relative to SC on HSCT-specific QOL. Outcomes will be collected at baseline pre-transplant (pre-YT) and then day 0, 14, 30, 60, and 100 as well as 1-year post-transplant.
Secondary Objectives and Endpoints:
- Examine group differences in other patient-reported outcomes including general QOL and fatigue.
- Explore group differences in psychosocial and functional outcomes and as possible mediators including stress, mental health (depression and anxiety), sleep disturbances, growth, self-efficacy, mindfulness, and objective functional measures as well as moderators of YT including demographic factors (sex, age, etc.), baseline psychosocial factors, and medical variables (e.g., autologous versus allogeneic transplant).
- Explore YT's implementation through qualitative interviews.
- Conditions
- Cancer
- Being tested
- Yoga Therapy (YT)
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Yoga Therapy (YT)Other
Yoga Therapy (YT) is an evidence-based mind-body practice recommended for cancer to relieve nausea, fatigue, pain, sleep disruption, psychosocial distress, musculoskeletal symptoms, and cognitive dysfunction, all common symptoms experienced during HSCT.
| Study group | Role | What they receive |
|---|---|---|
| SC: Enhanced Stand of Care Group | Experimental | In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first Receives: Other: Yoga Therapy (YT) |
| YT: Yoga Group | Experimental | In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first Receives: Other: Yoga Therapy (YT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start1 Feb 2027 (estimated)
- Primary completion13 Apr 2030 (estimated)
- Study completion13 Apr 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Responsible party
- Sponsor
- Investigators
- Lorenzo Cohen, PHD, Principal investigator, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07776587
- Sponsor's protocol ID
- 2026-1004
- Other IDs
- NCI-2026-06046
- Status last verified
- Aug 2026
- First submitted
- 17 Aug 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No